Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular risk markers in women with PCOS and NASH treated with liraglutide
2009-015927-94Phase 4Completed
- Sponsor
- Hull University Teaching Hospitals
- Start
- Mar 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, single-arm trial of liraglutide in polycystic ovary syndrome (PCOS) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Hull University Teaching Hospitals. Primary endpoints: Improvement in insulin resistance, Improvement in endothelial function and 2 more. Started Mar 2010; status: completed.
02
Drugs
03
Conditions
polycystic ovary syndrome (PCOS)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2009-015927-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015927-94.